x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers

On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs. Rahul & Rohit Gosain interview world-renowned hematologists/oncologists to present the practice-changing data in a small bite-sized format where one could immediately apply that information in their daily practice to provide the best cancer care to their patients close to home. Privacy Policy:

health & fitness medicine

All Episodes

00:24:33

ASH 2025 Multiple Myeloma Highlights – AQUILA, COBRA,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/19

Feeling overwhelmed by the rapid pace of change in multiple myeloma? ASH 2025 delivered potentially practice-changing data that could redefine second-line therapy and beyond.In this episode, we sat down with myeloma specialist Dr. Ben Derman from the University of Chicago to dissect the most critical studies. We moved from the controversial treatment of high-risk smoldering myeloma to head-to-head comparisons in newly diagnosed disease, and finally, to the groundbreaking bispecific antibody data

en

00:21:33

GI ASCO 2026 Highlights MATTERHORN, HERIZON-GEA-01,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/15

We’re kicking off 2026 with practice-changing data fresh from GI ASCO 2026. In this episode, we were joined once again by Dr. Rachna Shroff from the University of Arizona Cancer Center to break down the four most pivotal studies in upper GI and colorectal cancers presented at the GI ASCO 2026.We dived into the latest updates that will directly impact your clinical decisions, from new standards in perioperative therapy to revolutionary front-line regimens for metastatic disease.Key topics covered in

en

00:13:42

ASH 2025 Lymphoma Highlights - EPCORE FL-1, CLL-17,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/11

In this episode of the Oncology Brothers podcast, we were joined by Dr. Julie Vose, a leading expert in lymphoma from the University of Nebraska Medical Center. Together, we delved into the key abstracts presented at ASH 2025, focusing on significant studies in lymphoma and chronic lymphocytic leukemia (CLL).Episode Highlights:● EPCORE FL-1: the approval of Epcoritamab in combination with Rituximab and lenalidomide for relapsed refractory follicular lymphoma● CLL-17: comparison between continuous

en

00:17:03

ASH 2025 Leukemia Highlights PARADIGM, KOMET-007,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/07

In this episode of the Oncology Brothers podcast, we dived into the key highlights from ASH 2025, focusing on advancements in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).We welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss key studies from the leukemia space, including the PARADIGM trial comparing Azacitidine plus Venetoclax to traditional 7 + 3 induction chemotherapy for fit patients with newly diagnosed AML. We explore the implications of these findings,

en

00:23:03

HER2+ SABCS 2025 Highlights DESTINY...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/05

Join us as we dive into the latest advancements in HER2-positive breast cancer from SABCS 2025. In this episode, we discussed key studies including DESTINY Breast-11 and DESTINY Breast-05, highlighting their implications for neoadjuvant and adjuvant treatments. We also explored the HER2CLIMB-05 trial and the recent approval of TDXD with pertuzumab in frontline settings for metastatic HER2-positive disease.Special guest Dr. Harold Burstein from Dana-Farber Cancer Institute shared his insights on the

en

00:24:38

Triple Negative Breast Cancer SABCS 2025 Highlights:...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2026/01/03

In this episode of the Oncology Brothers podcast, we were joined by Dr. Rebecca Shatsky, a breast medical oncologist and director of the Inflammatory and Triple Negative Breast Cancer Program at UC San Diego. We dived into the latest findings from the SABCS 2025 conference, focusing on key studies related to triple negative breast cancer (TNBC).Join us as we discussed:* The RJBC 1501 study, which explored the role of carboplatin in high-risk early-stage TNBC and its impact on disease-free survival.*

en

00:19:44

Enfortumab vedotin + Pembro FDA Approval in Muscle...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/31

Join us for another insightful episode of the Oncology Brothers podcast, where we dived into the latest advancements in bladder cancer treatment! In this episode, we discussed the groundbreaking approval of Enfortumab vedotin (EV) combined with Pembrolizumab (Pembro) for cisplatin-ineligible muscle-invasive bladder cancer, based on the impressive results from the Keynote-905/EV-303 study.We are thrilled to have Dr. Tom Powles, a world-renowned GU medical oncologist, share his expertise on the study

en

00:23:33

Metastatic HR+ Breast Cancer SABCS 2025 Highlights:...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/26

Welcome to the Oncology Brothers podcast! In this episode, we dived into the key highlights from the SABCS 2025 conference, focusing on metastatic hormone receptor-positive breast cancer.Join us as we discussed:• The role of CDK4-6 inhibitors in frontline therapy, featuring updates from the AMBRE and MONALEESA-3 studies• Insights into second-line treatment options, including the VIKTORIA-1, evERA, EMBER-3, SERENA-6 trials• A critical look at the ASCENT-07 study, exploring the role of antibody-drug

en

00:15:50

Early HR+ Disease SABCS 2025 Practice...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/22

In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.Join us as we dive into three key abstracts:1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.2. lidERA Study: Learn about the promising data on the oral

en

00:09:44

Advancements and Challenges in Metastatic Colorectal...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/21

In this episode of the Oncology Brothers podcast, we dived into the latest discussions surrounding metastatic colorectal cancer, focusing on treatment strategies for refractory cases. We recapped our recent discussions with GI experts, including Dr. John Strickler, Dr. Chiara Cremolini, Dr. Namrata Vijayvergia, and Dr. Tiago Biachi.Key topics included:* The importance of next-generation sequencing (NGS) and biomarker testing in treatment planning.* An overview of second-line treatment options such

en

00:25:03

Clinical Implications of Testing HER2 and Targeted...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/19

In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.Key topics include:• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.• The definition and implications of low and ultra-low HER2 expression in clinical

en

00:17:49

Toxicity Management of HER2+ Treatment Options in...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/18

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University.Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on

en

00:14:47

Current Treatment Landscape of Advanced...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/15

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease.Episode Highlights:• Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings.• Discussion on the

en

00:24:38

Managing Toxicities of Antibody Drug Conjugates...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/13

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V).We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease

en

00:22:25

Managing Toxicities of PI3K & AKT Inhibitors in...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/11

Welcome to the Oncology Brothers podcast! In this episode, we welcomed Dr. Neil Iyengar and Dr. Emily Gallagher, to dive deep into the world of PIK3CA and AKT pathway inhibitors for hormone receptor-positive (HR+) metastatic breast cancer.We discussed the latest approvals, including Inavolisib, Alpelisib, and Capivasertib, and explored their common side effects such as hyperglycemia, rash, and gastrointestinal issues. Our experts shared practical management strategies, dosing considerations, and the

en

00:21:02

Challenging Cases of Iron Abnormalities, Anemia or...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/04

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral

en

00:21:31

FDA Approval of Epcoritamab-Rituximab-Lenalidomide...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/04

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting

en

00:21:31

FDA Approval of Epcoritamab-Rituximab-Lenalidomide...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/01

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting

en

00:22:36

Challenging Cases in Second Line & Beyond Renal Cell...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/30

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases.We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following

en

00:17:29

FDA Approval of Durvalumab with FLOT in Resectable...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/26

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice,

en

210 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown